Impact of Breast Cancer Subtype Defined by Immunohistochemistry Hormone Receptor and HER2 Status on the Incidence of Immediate Postmastectomy Reconstruction

Medicine
Wei WuMinghui Cao

Abstract

Immediate postmastectomy reconstruction has become an increasingly popular choice for breast cancer patients recently. However, whether molecular subtype of cancer impacts the incidence of breast reconstruction is unclear. We aimed to investigate the association between breast cancer subtype defined by immunohistochemistry hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status and recent rates of immediate postmastectomy reconstruction in the United States.The National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database was used to evaluate stage I-III breast cancer patients with different subtypes who underwent either mastectomy alone or mastectomy plus reconstruction between 2010 and 2012. Univariate and multivariate analyses were conducted to identify factors influencing the incidence of immediate reconstruction.Of 47,123 women included, 33.1% (10,712/32,376) of HR+/HER2-, 33.1% (1912/5768) of HR+/HER2+, 29.6% (850/2875) of HR-/HER2+, and 27.7% (1689/6104) of triple negative breast cancer patients received immediate breast reconstruction (chi-square test, P < 0.001), respectively. Thus, HER2-overexpressing and triple negative breast cancer patients received significantly l...Continue Reading

References

Sep 7, 2000·Journal of the National Cancer Institute·J H RowlandP A Ganz
Aug 24, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Roman RouzierLajos Pusztai
Jun 8, 2006·JAMA : the Journal of the American Medical Association·Lisa A CareyRobert C Millikan
Apr 18, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lisa A CareyCharles M Perou
Feb 7, 2008·Cancer·Hae-Chung YangBarbara L Andersen
Feb 28, 2008·Plastic and Reconstructive Surgery·Colleen M McCarthyPeter G Cordeiro
Apr 9, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J Fernández-DelgadoM M Reza
Jun 27, 2008·Annals of Plastic Surgery·Lisbet Rosenkrantz HölmichSøren Friis
Mar 25, 2009·American Journal of Surgery·Brian C ReubenLeigh A Neumayer
May 26, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hagen KenneckeKaren Gelmon
Dec 15, 2010·Molecular Oncology·Aleix Prat, Charles M Perou
May 24, 2011·The Breast : Official Journal of the European Society of Mastology·Thomas NedumparaMichael R Williams
Dec 8, 2011·Breast Cancer Research and Treatment·Aoife J LoweryKarl J Sweeney
Jan 10, 2012·Journal of the American College of Surgeons·Beth Aviva PremingerChristine Rohde
Dec 25, 2012·Annals of Surgical Oncology·Haejin InCaprice C Greenberg
Jan 15, 2013·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·M C KneubilM Rietjens
Feb 14, 2015·The Journal of Surgical Research·Anaeze C OffodileLifei Guo

❮ Previous
Next ❯

Citations

Oct 15, 2021·Journal of Racial and Ethnic Health Disparities·Shahnjayla K ConnorsSarah Gehlert

❮ Previous
Next ❯

Software Mentioned

STATA

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.